This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
Some of the effectiveness data were derived from the literature, and were used as inputs for the model. Only the modelled scores on the cognitive subscale of the AD assessment scale (ADAS-cog) were reported in the study. The health utility values for the two states of the model, pre-FTC and FTC, were also derived from the published data.
Study designs and other criteria for inclusion in the review
The data inputs for the model were derived from randomised double-blind clinical trials. The utility values for specific AD states were derived from a cross-sectional study.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
Three primary studies were selected for the effectiveness analysis.
Methods of combining primary studies
The data from two clinical trials were pooled, but the method used to combine the data was not reported.
Investigation of differences between primary studies
Results of the review
The average modelled ADAS-cog score was 24.9 for patients treated with galantamine and 27.5 for non-treated patients. The utility value was 0.60 for the pre-FTC state and 0.34 for the FTC state.
Measure of benefits used in the economic analysis
The benefit measures used in the economic analysis were the percentage reduction in the time requiring FTC, the percentage increase in the time spent in the pre-FTC state, and the number of quality-adjusted life-years (QALYs) gained.
Direct costs
The costs were incurred over a period of 10 years and were discounted at a rate of 3%. The quantities and the unit costs were reported separately by visit or per day. The resource/cost boundary adopted was that of the health service. Only the costs of formal care were included in the analysis. These included the drugs, medical costs and paid home help. The costs of adverse events associated with galantamine were excluded because the impact on resource use was very low. The unit cost data were taken from different sources. These included insurance plan listings, professional organisations, government agencies, physician fee schedules, and the Canadian Coordinating Office for Health Technology Assessment. The total costs in each health state were estimated by modelling. The resource use data were gathered in 1997 and 2000. The price year was 1999. Instead, they were derived from estimations from different studies. However, although these studies were pooled, the method used to combine them was not stated clearly. No details were provided of the search strategies used to identify the studies. In addition, the criteria used to ensure the validity of the primary studies were not reported.
Validity of estimate of measure of benefit
The estimated benefits (reduction or increase in time, and QALYs) used in the economic analysis were modelled. However, it would have been interesting to use utility values from patients, as well as informal caregivers whose quality of life is heavily affected by AD patients.
Validity of estimate of costs
The cost estimates were quite specific to the study setting. The unit costs and the quantities were reported separately, although statistical analyses on the quantities were not conducted. The perspective of the study was not stated. Some of the costs relevant to the analysis could, therefore, have been omitted or erroneously included. A limitation of the analysis could have been the exclusion of indirect costs, which appear to have been relevant, due to the high expenditures borne by people caring for patients suffering from AD.
Other issues
The generalisability of the results to other settings was specifically addressed by a sensitivity analysis, although the ranges were arbitrary. However, the authors did not compare their findings with those from other studies. The authors acknowledged some limitations of the study. For example, data relating to the burden on the informal caregiver, in terms of the cost of their time and their quality of life, were excluded.
